OncoNOx Overview

  • Founded
  • 2011
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

OncoNOx General Information


Developer of drugs designed to target disease-specific pathogenetic pathways. The company's drugs are created with proprietary compounds by hybridization of known drugs with nitric oxide groups, enabling patients to begin treatment more quickly and result in a higher likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Ole Maaløes Vej 3
  • 2200 Copenhagen
  • Denmark
+45 21 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoNOx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Generating Revenue
1. Seed Round 16-Sep-2011 Completed Generating Revenue
To view OncoNOx’s complete valuation and funding history, request access »

OncoNOx Executive Team (6)

Name Title Board Seat Contact Info
Gianni Garotta Ph.D Co-Founder & Board Member
Marco Donia MD Co-Founder
Yousef Al-Abed Co-Founder
Mai-Britt Zocca Ph.D Co-Founder, Chief Executive Officer & Board Member
Ferdinando Nicoletti MD Co-Founder, Chief Scientific Officer & Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

OncoNOx Board Members (4)

Name Representing Role Since
Ferdinando Nicoletti MD Self Co-Founder, Chief Scientific Officer & Chairman 000 0000
Gianni Garotta Ph.D OncoNOx Co-Founder & Board Member 000 0000
You’re viewing 2 of 4 board members. Get the full list »